Publication date: Feb 12, 2020
Every year, new drugs enter the market, but only a select few come bearing blockbuster potential.
According to the Drugs to Watch in 2020 list compiled by Cortellis, these 11 would-be blockbusters span several therapeutic areas, including central nervous system (CNS), oncology, hematology, inflammatory diseases and metabolic disorders.
The Novartis drug’s subcutaneous dosing could set it apart from Ocrevus’ intravenous infusion route.
Between Bristol and Novartis, each has a second drug on the list.
Outside of the BMS and Novartis MS candidates, the third CNS drug on Cortellis’ blockbuster potential list is Biohaven Pharmaceutical’s oral CGRP antagonist rimegepant for migraine.
RELATED: AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U. S. launch Cancer therapies also occupy three spots on this year’s roster.
After a manufacturing-related complete response letter in early 2019, Immunomedics has refiled the drug for triple-negative breast cancer after two prior therapies.
While the injectable form of the drug, Ozempic, is already delivering blockbuster global sales, Rybelsus is widely viewed as a disrupter of the Type 2 diabetes landscape thanks to its oral status.
Remaining drugs on the list include Akebia Therapeutics, Mitsubishi Tanabe and Otsuka’s HIF-PH inhibitor anemia drug vadadustat, which competes against FibroGen, Astellas and AstraZeneca’s Evrenzo (roxadustat); Gilead’s rheumatoid arthritis contender filgotinib, which belongs to the same JAK inhibitor class as Pfizer’s Xeljanz, Eli Lilly’s Olumiant and AbbVie’s Rinvoq; and BioMarin’s hemophilia A gene therapy valrox that’s aiming to poach Roche drug Hemlibra’s market share.
|drug||DRUGBANK||Calcitonin gene-related peptide|
|disease||MESH||Type 2 diabetes|
|disease||MESH||triple-negative breast cancer|